Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients with CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials

American Journal of Kidney Diseases

Volumn 67, Issue 5, 2016, Pages 728-741

  Xie, Xinfang ^a,b,c,d   Liu, Youxia ^a,b,c,d   Perkovic, Vlado ^e   Li, Xiangling ^f   Ninomiya, Toshiharu ^e   Hou, Wanyin ^a,b,c,d   Zhao, Na ^a,b,c,d   Liu, Lijun ^a,b,c,d   Lv, Jicheng ^a,b,c,d,e   Zhang, Hong ^a,b,c,d   Wang, Haiyan ^a,b,c,d  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b PEKING UNIVERSITY   (China)

^c China Ministry of Health   (China)

^d Ministry of Education   (China)

^e UNIVERSITY OF SYDNEY   (Australia)

^f WEIFANG MEDICAL UNIVERSITY   (China)

Author keywords

all cause death; angiotensin II receptor blocker (ARB); Bayesian network meta analysis; blood pressure (BP); cardiovascular events; chronic kidney disease (CKD); comparative effectiveness; hypertension; Index Words Angiotensin converting enzyme (ACE) inhibitor; kidney failure; mortality; renal disease progression; renin angiotensin system (RAS) inhibition

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO;

ANGIONEUROTIC EDEMA; BAYES THEOREM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; COUGHING; DRUG EFFECT; EDEMA; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY FAILURE; META ANALYSIS; MORTALITY; PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; CARDIOVASCULAR DISEASES; KIDNEY FAILURE, CHRONIC; RENAL INSUFFICIENCY, CHRONIC;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BAYES THEOREM; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY FAILURE, CHRONIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 84948823375     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2015.10.011     Document Type: Article

References (138)

1. M.T. James, B.R. Hemmelgarn, and M. Tonelli Early recognition and prevention of chronic kidney disease Lancet 375 9722 2010 1296 1309
2. M. Tonelli, P. Muntner, A. Lloyd, and et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study Lancet 380 9844 2012 807 814
3. C.A. Herzog, R.W. Asinger, A.K. Berger, and et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney Int 80 6 2011 572 586
4. V. Perkovic, T. Ninomiya, H. Arima, and et al. Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study J Am Soc Nephrol 18 10 2007 2766 2772
5. J.F. Mann, H.C. Gerstein, J. Pogue, J. Bosch, and S. Yusuf Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial Ann Intern Med 134 8 2001 629 636
6. P. Ruggenenti, A. Perna, G. Gherardi, and et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria Lancet 354 9176 1999 359 364
7. B.M. Brenner, M.E. Cooper, D. de Zeeuw, and et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 12 2001 861 869
8. T. Berl, L.G. Hunsicker, J.B. Lewis, and et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy Ann Intern Med 138 7 2003 542 549
9. S. Yusuf, K.K. Teo, J. Pogue, and et al. Telmisartan, ramipril, or both in patients at high risk for vascular events N Engl J Med 358 15 2008 1547 1559
10. KDIGO Blood Pressure Work Group KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease Kidney Int Suppl 2 2012 337 414
11. P.A. James, S. Oparil, B.L. Carter, and et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) JAMA 311 5 2014 507 520
12. M. Rahman, S. Pressel, B.R. Davis, and et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate Ann Intern Med 144 3 2006 172 180
13. G. Mancia, R. Fagard, K. Narkiewicz, and et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur Heart J 34 28 2013 2159 2219
14. A. Liberati, D.G. Altman, J. Tetzlaff, and et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration Ann Intern Med 151 4 2009 W65 W94
15. Dias S, Welton N, Sutton AJ, Ades AE. Appendix A: WinBUGS code used in Bayesian mixed treatment comparisons meta-analysis. In: NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. 2011; last updated March 2013. http://www.nicedsu.org.uk/TSD2%20General%20meta%20analysis%20corrected%2015April2014.pdf. Accessed January 2, 2015.
16. Brooks SP, and A. Gelman Alternative methods for monitoring convergence of iterative simulations J Comput Graph Stat 7 1998 434 435
17. S. Dias, N.J. Welton, D.M. Caldwell, and A.E. Ades Checking consistency in mixed treatment comparison meta-analysis Stat Med 29 7-8 2010 932 944
18. F. Song, T. Xiong, S. Parekh-Bhurke, and et al. Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study BMJ 343 2011 d4909
19. G. Salanti, A.E. Ades, and J.P. Ioannidis Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial J Clin Epidemiol 64 2 2011 163 171
20. H.J. Heerspink, T. Ninomiya, V. Perkovic, and et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease Eur Heart J 31 23 2010 2888 2896
21. J.J. Brugts, E. Boersma, M. Chonchol, and et al. The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial J Am Coll Cardiol 50 22 2007 2148 2155
22. S.D. Solomon, M.M. Rice, K. A Jablonski, and et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial Circulation 114 1 2006 26 31
23. F. Zannad, M. Kessler, P. Lehert, and et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies Kidney Int 70 7 2006 1318 1324
24. F.F. Hou, X. Zhang, G.H. Zhang, and et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency N Engl J Med 354 2 2006 131 140
25. P.C. Tong, G.T. Ko, W.B. Chan, and et al. The efficacy and tolerability of fosinopril in Chinese type 2 diabetic patients with moderate renal insufficiency Diabetes Obes Metab 8 3 2006 342 347
26. M.P. Tokmakova, H. Skali, S. Kenchaiah, and et al. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study Circulation 110 24 2004 3667 3673
27. F.W. Asselbergs, G.F. Diercks, H.L. Hillege, and et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria Circulation 110 18 2004 2809 2816
28. M. Marre, M. Lievre, G. Chatellier, and et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study) BMJ 328 7438 2004 495
29. S. Katayama, R. Kikkawa, S. Isogai, and et al. Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM) Diabetes Res Clin Pract 55 2 2002 113 121
30. P. O'Hare, R. Bilbous, T. Mitchell, C.J. O'Callaghan, and G.C. Viberti Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial Diabetes Care 23 12 2000 1823 1829
31. G. Crepaldi, Q. Carta, G. Deferrari, and et al. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM Diabetes Care 21 1 1998 104 110
32. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy Lancet 349 9069 1997 1857 1863
33. J. Ahmad, M.A. Siddiqui, and H. Ahmad Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria Diabetes Care 20 10 1997 1576 1581
34. G. Maschio, D. Alberti, G. Janin, and et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group N Engl J Med 334 15 1996 939 945
35. B.U. Ihle, J.A. Whitworth, S. Shahinfar, and et al. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial Am J Kidney Dis 27 4 1996 489 495
36. The Microalbuminuria Captopril Study Group. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria Diabetologia 39 5 1996 587 593
37. R. Trevisan, and A. Tiengo Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group Am J Hypertens 8 9 1995 876 883
38. L.M. Laffel, J.B. McGill, and D.J. Gans The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group Am J Med 99 5 1995 497 504
39. G. Viberti, C.E. Mogensen, L.C. Groop, and J.F. Pauls Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group JAMA 271 4 1994 275 279
40. E.J. Lewis, L.G. Hunsicker, R.P. Bain, and R.D. Rohde The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group N Engl J Med 329 20 1993 1456 1462
41. J.H. Bauer, G.P. Reams, J. Hewett, and et al. A randomized, double-blind, placebo-controlled trial to evaluate the effect of enalapril in patients with clinical diabetic nephropathy Am J Kidney Dis 20 5 1992 443 457
42. L. Foucan, V. Bourhis, J. Bangou, and et al. A randomized trial of captopril for microalbuminuria in normotensive adults with sickle cell anemia Am J Med 104 4 1998 339 342
43. M. Capek, C. Schnack, B. Ludvik, and et al. Effects of captopril treatment versus placebo on renal function in type 2 diabetic patients with microalbuminuria: a long-term study Clin Invest 72 12 1994 961 966
44. M. Ravid, H. Savin, I. Jutrin, and et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients Ann Intern Med 118 8 1993 577 581
45. M. Bojestig, B.E. Karlberg, T. Lindstrom, and F.H. Nystrom Reduction of ACE activity is insufficient to decrease microalbuminuria in normotensive patients with type 1 diabetes Diabetes Care 24 5 2001 919 924
46. M.J. O'Donnell, B.R. Rowe, N. Lawson, and et al. Placebo-controlled trial of lisinopril in normotensive diabetic patients with incipient nephropathy J Hum Hypertens 7 4 1993 327 332
47. N. Matsumoto, T. Ishimitsu, A. Okamura, and et al. Effects of imidapril on left ventricular mass in chronic hemodialysis patients Hypertens Res 29 4 2006 253 260
48. A. Nankervis, K. Nicholls, G. Kilmartin, and et al. Effects of perindopril on renal histomorphometry in diabetic subjects with microalbuminuria: a 3-year placebo-controlled biopsy study Metabolism 47 12 suppl 1 1998 12 15
49. W.C. Yu, Y.P. Lin, I.F. Lin, S.Y. Chuang, and C.H. Chen Effect of ramipril on left ventricular mass in normotensive hemodialysis patients Am J Kidney Dis 47 3 2006 478 484
50. C.B. Bowling, P.W. Sanders, R.M. Allman, and et al. Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD treatment trial Int J Cardiol 167 1 2013 151 156
51. E. Imai, J.C. Chan, S. Ito, and et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study Diabetologia 54 12 2011 2978 2986
52. S.W. Tobe, C.M. Clase, P. Gao, and et al. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies Circulation 123 10 2011 1098 1107
53. P.K. Li, C.B. Leung, K.M. Chow, and et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study Am J Kidney Dis 47 5 2006 751 760
54. H.H. Parving, H. Lehnert, J. Brochner-Mortensen, and et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 345 12 2001 870 878
55. H. Makino, M. Haneda, T. Babazono, and et al. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of the Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study Hypertens Res 31 4 2008 657 664
56. K.D. Kjaergaard, C.D. Peters, B. Jespersen, and et al. Angiotensin blockade and progressive loss of kidney function in hemodialysis patients: a randomized controlled trial Am J Kidney Dis 64 6 2014 892 901
57. R. Yilmaz, B. Altun, S. Kahraman, and et al. Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients Ren Fail 32 8 2010 903 912
58. R. Zeltner, R. Poliak, B. Stiasny, R.E. Schmieder, and B.D. Schulze Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease Nephrol Dial Transplant 23 2 2008 573 579
59. V.L. Esnault, E.A. Brown, E. Apetrei, and et al. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study Clin Ther 30 3 2008 482 498
60. K. Norris, J. Bourgoigne, J. Gassman, and et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) trial Am J Kidney Dis 48 5 2006 739 751
61. G.H. Zhang, F.F. Hou, X. Zhang, and Q.F. Liu [Can angiotensin-converting enzyme inhibitor be used in chronic kidney disease patients with serum creatinine level greater than 266 micromol/L?] Zhonghua Nei Ke Za Zhi 44 8 2005 592 596
62. M.S. MacGregor, C.J. Deighan, R.S. Rodger, and J.M. Boulton-Jones A prospective open-label randomised trial of quinapril and/or amlodipine in progressive non-diabetic renal failure Nephron Clin Pract 101 3 2005 c139 c149
63. M. Dalla Vestra, G. Pozza, A. Mosca, and et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina) Diabetes Nutr Metab 17 5 2004 259 266
64. M. Marre, J.G. Puig, F. Kokot, and et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study J Hypertens 22 8 2004 1613 1622
65. P.K. Li, K.M. Chow, T.Y. Wong, C.B. Leung, and C.C. Szeto Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study Ann Intern Med 139 2 2003 105 112
66. M.A. van Dijk, M.H. Breuning, R. Duiser, L.A. van Es, and R.G. Westendorp No effect of enalapril on progression in autosomal dominant polycystic kidney disease Nephrol Dial Transplant 18 11 2003 2314 2320
67. M. Praga, E. Gutierrez, E. Gonzalez, E. Morales, and E. Hernandez Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial J Am Soc Nephrol 14 6 2003 1578 1583
68. R. Marin, L.M. Ruilope, P. Aljama, and et al. A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease J Hypertens 19 10 2001 1871 1876
69. H. Herlitz, K. Harris, T. Risler, and et al. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study Nephrol Dial Transplant 16 11 2001 2158 2165
70. G.A. Cinotti, and P.C. Zucchelli Effect of lisinopril on the progression of renal insufficiency in mild proteinuric non-diabetic nephropathies Nephrol Dial Transplant 16 5 2001 961 966
71. L.J. Petersen, J.R. Petersen, U. Talleruphuus, and et al. A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension Clin Nephrol 55 5 2001 375 383
72. L. Tarnow, P. Rossing, C. Jensen, B.V. Hansen, and H.H. Parving Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy Diabetes Care 23 12 2000 1725 1730
73. H. Kumagai, K. Hayashi, H. Kumamaru, and T. Saruta Amlodipine is comparable to angiotensin-converting enzyme inhibitor for long-term renoprotection in hypertensive patients with renal dysfunction: a one-year, prospective, randomized study Am J Hypertens 13 9 2000 980 985
74. G.G. van Essen, A.J. Apperloo, P.L. Rensma, and et al. Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline? Kidney Int Suppl 63 1997 S58 S62
75. F.S. Nielsen, P. Rossing, M.A. Gall, and et al. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy Diabetes 46 7 1997 1182 1188
76. G.L. Bakris, J.B. Copley, N. Vicknair, R. Sadler, and S. Leurgans Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy Kidney Int 50 5 1996 1641 1650
77. T. Sano, N. Hotta, T. Kawamura, and et al. Effects of long-term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients: results of a 4-year, prospective, randomized study Diabet Med 13 2 1996 120 124
78. L.D. Elving, J.F. Wetzels, H.J. van Lier, E. de Nobel, and J.H. Berden Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Results of a 2-year prospective, randomized study Diabetologia 37 6 1994 604 609
79. T. Hannedouche, P. Landais, B. Goldfarb, and et al. Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure BMJ 309 6958 1994 833 837
80. S. Bjorck, H. Mulec, S.A. Johnsen, G. Norden, and M. Aurell Renal protective effect of enalapril in diabetic nephropathy BMJ 304 6823 1992 339 343
81. A.L. Kamper, S. Strandgaard, and P.P. Leyssac Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial Am J Hypertens 5 7 1992 423 430
82. P. Zucchelli, A. Zuccala, M. Borghi, and et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency Kidney Int 42 2 1992 452 458
83. PROCOPA Study Group. Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomized double-blind trial J Hypertens 20 4 2002 729 737
84. R. Fogari, A. Zoppi, L. Corradi, and et al. Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function J Hum Hypertens 13 1 1999 47 53
85. Y.K. Seedat, and I.G. Randeree Antihypertensive effect and tolerability of perindopril in Indian hypertensive and type 2 diabetic patients: 1-year randomised, double-blind, parallel study vs atenolol Clin Drug Investig 16 3 1998 229 240
86. X. Shi, X. Chen, S. Liu, Y. Zhuang, and Y. Zhang [The effects of angiotensin-converting enzyme inhibitor on IgA nephropathy and the influencing factors] Zhonghua Nei Ke Za Zhi 41 6 2002 399 403
87. C. Schnack, W. Hoffmann, P. Hopmeier, and G. Schernthaner Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria Diabetologia 39 12 1996 1611 1616
88. Melbourne Diabetic Nephropathy Study Group. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria BMJ 302 6770 1991 210 216
89. C.D. Agardh, J. Garcia-Puig, B. Charbonnel, B. Angelkort, and A.H. Barnett Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine J Hum Hypertens 10 3 1996 185 192
90. R. Fogari, A. Mugellini, A. Zoppi, and et al. Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria Eur J Clin Pharmacol 61 7 2005 483 490
91. R. Rachmani, I. Slavachevsky, M. Amit, and et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study Diabet Med 21 5 2004 471 475
92. Z.A. Fogari Roberto, L. Corradi, L. Poletti, M. Pasotti, E. Fogari, and A. Mugellini Long-term effects of amlodipine versus fosinopril on microalbuminuria in elderly hypertensive patients with type 2 diabetes mellitus Curr Ther Res 61 3 2000 163 173
93. R. Agarwal, A.D. Sinha, M.K. Pappas, T.N. Abraham, and G.G. Tegegne Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial Nephrol Dial Transplant 29 3 2014 672 681
94. T. Shiga, H. Kasanuki, N. Hagiwara, and et al. Angiotensin receptor blocker-based therapy and cardiovascular events in hypertensive patients with coronary artery disease and impaired renal function Blood Press 19 6 2010 359 365
95. T. Saruta, K. Hayashi, T. Ogihara, and et al. Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study Hypertens Res 32 6 2009 505 512
96. H. Suzuki, Y. Kanno, S. Sugahara, and et al. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial Am J Kidney Dis 52 3 2008 501 506
97. T. Uzu, M. Sawaguchi, H. Maegawa, and A. Kashiwagi Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART) Diabetes Care 30 6 2007 1581 1583
98. A. Takahashi, H. Takase, T. Toriyama, and et al. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis-a randomized study Nephrol Dial Transplant 21 9 2006 2507 2512
99. K. Nutahara, E. Higashihara, S. Horie, and et al. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease Nephron Clin Pract 99 1 2005 c18 c23
100. T. Nakamura, Y. Kanno, T. Takenaka, and H. Suzuki An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency Hypertens Res 28 5 2005 415 423
101. M. Usta, A. Ersoy, K. Dilek, and et al. Efficacy of losartan in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatment J Intern Med 253 3 2003 329 334
102. G. Viberti, and N.M. Wheeldon Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect Circulation 106 6 2002 672 678
103. M.J. Krimholtz, J. Karalliedde, S. Thomas, R. Bilous, and G. Viberti Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease J Am Soc Nephrol 16 suppl 1 2005 S42 S47
104. K. Iseki, H. Arima, K. Kohagura, and et al. Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial Nephrol Dial Transplant 28 6 2013 1579 1589
105. H. Rakugi, T. Ogihara, S. Umemoto, and et al. Combination therapy for hypertension in patients with CKD: a subanalysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events trial Hypertens Res 36 11 2013 947 958
106. T. Yasuda, M. Endoh, D. Suzuki, and et al. Effects of valsartan on progression of kidney disease in Japanese hypertensive patients with advanced, predialysis, chronic kidney disease: Kanagawa Valsartan Trial (KVT) Hypertens Res 36 3 2013 240 246
107. T. Mimura, T. Takenaka, Y. Kanno, and et al. Vascular compliance is secured under angiotensin inhibition in non-diabetic chronic kidney diseases J Hum Hypertens 22 1 2008 38 47
108. P.K.T. Li, B.C.H. Kwan, K.M. Chow, C.B. Leung, and C.C. Szeto Treatment of early immunoglobulin A nephropathy by angiotensin-converting enzyme inhibitor Am J Med 126 2 2013 162 168
109. F.F. Hou, D. Xie, X. Zhang, and et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency J Am Soc Nephrol 18 6 2007 1889 1898
110. A.H. Barnett, S.C. Bain, P. Bouter, and et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy N Engl J Med 351 19 2004 1952 1961
111. F.A. Reyes-Marin, C. Calzada, A. Ballesteros, and D. Amato Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. A randomized controlled study Rev Invest Clin 64 4 2012 315 321
112. K.T. Woo, C.M. Chan, H.K. Tan, and et al. Beneficial effects of high-dose losartan in IgA nephritis Clin Nephrol 71 6 2009 617 624
113. J. Shoda, Y. Kanno, and H. Suzuki A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy Intern Med 45 4 2006 193 198
114. O. Deyneli, D. Yavuz, A. Velioglu, and et al. Effects of ACE inhibition and angiotensin II receptor blockade on glomerular basement membrane protein excretion and charge selectivity in type 2 diabetic patients J Renin Angiotensin Aldosterone Syst 7 2 2006 98 103
115. M.C. de Gracia, M. Molina, M.J. Navarro, and M.A. Garcia Hernandez [Effect of irbesartan in proteinuric non-diabetic renal disease] Nefrologia 25 5 2005 509 514
116. Y. Lacourciere, A. Belanger, C. Godin, and et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy Kidney Int 58 2 2000 762 769
117. H.H. Parving, F. Persson, J.B. Lewis, E.J. Lewis, and N.K. Hollenberg Aliskiren combined with losartan in type 2 diabetes and nephropathy N Engl J Med 358 23 2008 2433 2446
118. U.F. Mehdi, B. Adams-Huet, P. Raskin, G.L. Vega, and R.D. Toto Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy J Am Soc Nephrol 20 12 2009 2641 2650
119. G. Cice, A. Di Benedetto, S. D'Isa, and et al. Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial J Am Coll Cardiol 56 21 2010 1701 1708
120. Y. Kanno, T. Takenaka, T. Nakamura, and H. Suzuki Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors Clin J Am Soc Nephrol 1 4 2006 730 737
121. H.H. Parving, B.M. Brenner, J.J. McMurray, and et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes N Engl J Med 367 23 2012 2204 2213
122. L.F. Fried, N. Emanuele, J.H. Zhang, and et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy N Engl J Med 369 20 2013 1892 1903
123. R.W. Schrier, K.Z. Abebe, R.D. Perrone, and et al. Blood pressure in early autosomal dominant polycystic kidney disease N Engl J Med 371 24 2014 2255 2266
124. V.E. Torres, K.Z. Abebe, A.B. Chapman, and et al. Angiotensin blockade in late autosomal dominant polycystic kidney disease N Engl J Med 371 24 2014 2267 2276
125. E.J. Lewis, L.G. Hunsicker, W.R. Clarke, and et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 12 2001 851 860
126. S. Ogawa, K. Takeuchi, T. Mori, and et al. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy Hypertens Res 30 4 2007 325 334
127. N. Muirhead, B.F. Feagan, and J. Mahon The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial Curr Ther Res 60 12 2000 650 660
128. G. Fernandez Juarez, J. Luno, V. Barrio, and et al. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial Am J Kidney Dis 61 2 2013 211 218
129. Y.H. Huang, H.T. Wang, Q.Z. Zhu, and et al. [Combination therapy with losartan and fosinopril for early diabetic nephropathy] Di Yi Jun Yi Da Xue Xue Bao 23 9 2003 963 965
130. M. Bilic, R. Munjas-Samarin, D. Ljubanovic, I. Horvatic, and K. Galesic Effects of ramipril and valsartan on proteinuria and renal function in patients with nondiabetic proteinuria Coll Antropol 35 4 2011 1061 1066
131. H. Suzuki, Y. Kanno, K. Kaneko, and et al. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy Ther Apher Dial 8 4 2004 320 327
132. Y. Horita, M. Tadokoro, K. Taura, and et al. Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy Hypertens Res 27 12 2004 963 970
133. F.D. Fuchs The role of angiotensin receptor blockers in the prevention of cardiovascular and renal disease: time for reassessment? Evid Based Med 18 2 2013 44 47
134. F. Turnbull, B. Neal, M. Pfeffer, and et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system J Hypertens 25 5 2007 951 958
135. L.C. van Vark, M. Bertrand, K.M. Akkerhuis, and et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients Eur Heart J 33 16 2012 2088 2097
136. H.Y. Wu, J.W. Huang, H.J. Lin, and et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis BMJ 347 2013 f6008
137. T. Ninomiya, V. Perkovic, F. Turnbull, and et al. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials BMJ 347 2013 f5680
138. H.J. Heerspink, T. Ninomiya, S. Zoungas, and et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials Lancet 373 9668 2009 1009 1015